Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro

Aras, Yavuz; ERGÜVEN, MİNE; Aktas, Esin; YAZIHAN, NURAY; Bilir, Ayhan

doi:10.1080/01616412.2016.1203096

Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro

Aras Y., ERGÜVEN M., Aktas E., YAZIHAN N., Bilir A.

NEUROLOGICAL RESEARCH, cilt.38, sa.9, ss.766-774, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 38 Sayı: 9
Basım Tarihi: 2016
Doi Numarası: 10.1080/01616412.2016.1203096
Dergi Adı: NEUROLOGICAL RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.766-774
Anahtar Kelimeler: Imatinib mesylate, Lithium chloride, Midkine, Glioblastoma, Antagonism, BETA-CATENIN, MIDKINE, INHIBITION, EXPRESSION, AUTOPHAGY, ACTIVATION, MECHANISMS, ARREST
Ankara Üniversitesi Adresli: Evet

Özet

Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro.